Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + VIC-1911
- Development stage
- Phase 2
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lenvatinib + VIC-1911 is an investigational combination therapy for advanced hepatocellular carcinoma (HCC), particularly in patients who are unresponsive or resistant to lenvatinib monotherapy. Lenvatinib is a small molecule multikinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1–3), fibroblast growth factor receptors (FGFR1–4), platelet-derived growth factor receptor alpha (PDGFRα), RET proto-oncogene, and KIT proto-oncogene. It inhibits tumor angiogenesis and proliferation. VIC-1911 (also known as TAS-119 or TAS-2104) is a highly selective oral small molecule inhibitor of aurora kinase A (AURKA), which plays a critical role in mitotic spindle formation and cell division; its inhibition leads to cell cycle arrest and apoptosis in cancer cells. The combination aims to overcome resistance mechanisms by targeting both angiogenesis pathways and mitotic regulation[2][3][10].
- Other names
- lenvatinib + VIC1911
02
Targets
AURKA (Aurora kinase A)AURKC (Aurora kinase C)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on lenvatinib + VIC-1911.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + VIC-1911.